MedTrace Logo

Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer

NCT05475847 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-07-28

No results posted yet for this study

Summary

A study that aimed to assess the safety and anti-tumor activity of C-TIL052A cell therapy in subjects with persistent, recurrent and/or metastatic cervical cancer.

Conditions

Interventions

BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection

C-TIL052A injection followed by injection of IL-2

Sponsors & Collaborators

  • Shanghai AbelZeta Ltd.

    collaborator INDUSTRY

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaohua Wu, MD, Ph.D · Fudan University

  • Jian Zhang, MD, Ph.D · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05475847 on ClinicalTrials.gov